Efficacy and Safety of Shengmai Preparation Combined with Western Medicine for Coronary Heart Disease: A Systematic Review and Meta-Analysis

Abstract

The efficacy and safety of Shengmai preparation combined with Western medicine (SMP–WM) to treat coronary heart disease (CHD) were reviewed. Twenty-five randomized controlled trials of SMP–WM treatment for CHD were retrieved from seven databases and other trial sources between their inception and April 10, 2021. The risk of bias domains was accessed by Cochrane Collaboration’s tool, and the data were statistically analyzed using RevMan 5.3 and Stata 12.0 software. The majority of included studies had a low or unclear risk of overall bias. Total mortality was not reduced (RR = 0.39, 95% CI: 0.13–1.19, [Formula: see text] = 0.10), but the cardiovascular events (RR = 0.35, 95% CI: 0.22–0.54, [Formula: see text] < 0.01), weekly frequency (SMD = −2.38, 95% CI: −2.89 – −1.88, [Formula: see text] < 0.01), and duration (SMD = −3.24, 95% CI: −3.76 – −2.71, [Formula: see text] < 0.01) of angina pectoris attacks were significantly decreased by SMP–WM. The SMP–WM combination exerted antiplatelet activity by reducing platelet adhesion (SMD = −0.97, 95% CI: −1.49 – −0.45, [Formula: see text] = 0.0003) and the platelet reactivity index (SMD = −1.75, 95% CI: −2.04 – −1.46, [Formula: see text] < 0.01). SMP–WM could protect endothelial function by increasing nitric oxide (SMD = 1.28, 95% CI: 0.54–2.02, [Formula: see text] < 0.01) and decreasing endothelin (SMD = −1.26, 95% CI: −1.85 – −0.66, [Formula: see text] < 0.01). The combination also improved hemorheology by reducing whole blood viscosity (SMD = −1.59, 95% CI: −2.32 – −0.85, [Formula: see text] < 0.01), plasma viscosity (SMD = −0.65, 95% CI: −0.86 – −0.45, [Formula: see text] < 0.01), and fibrinogen (SMD = −4.21, 95% CI: −4.58 – −3.83, [Formula: see text] < 0.01). The SMP–WM combination favorably impacts cardiovascular events, angina symptoms, endothelial function, platelet aggregation, and blood viscosity, with comparable safety to that of routine Western medicine. Further investigation is required to enhance the strength of the evidence.

Efficacy and safety of oral Chinese patent medicines in the treatment of coronary heart disease combined with hyperlipidemia: a systematic review and network meta-analysis of 78 trials

“…The total clinical effectiveness rate was studied as an outcome measure in 62 RCTs [ 15 – 19 , 21 – 28 , 30 – 32 , 34 – 38 , 40 – 42 , 46 – 48 , 50 – 52 , 54 , 55 , 57 – 63 , 65 , 66 , 68 – 80 , 83 , 84 , 86 , 87 , 89 – 92 ], covering 8 Chinese patent medicines and 6482 patients. These studies directly compared different intervention measures without forming a closed loop.…”

“…The incidence of AEs was calculated in 24 RCTs [ 18 , 25 , 45 – 50 , 53 , 54 , 57 , 62 , 64 , 66 , 71 , 76 , 78 , 81 – 83 , 85 , 87 , 90 , 92 ], 13 [ 25 , 45 , 46 , 48 , 53 , 54 , 57 , 62 , 66 , 71 , 76 , 87 , 90 ] of which reported the occurrence of AEs (Additional file 27 ). The difference in the incidence of AEs between the experimental and control groups in each study was not statistically significant (P > 0.05).…”

The application of dual-heart nursing mode in patients with coronary heart disease and angina pectoris and its impact on anxiety, depression, and quality of life

“…The chi square values of the 3 groups were 7.016, 6.953, and 6.874, respectively, and the value of experimental group 1 was the highest, and P < .01 of the 3 groups of patients, indicating that these data were statistically significant. [26][27][28] In addition, this project also aimed at the patients in the 3 groups, and studied their own acceptance scores after treatment, including patients' scores on their own condition, morphological stability and pathological characteristics. The self-evaluation of patients in experimental group 1 was the highest among the 3 groups, 89.72 ± 4.28, 67.65 ± 3.85, and 52.83 ± 3.20 in E2 and C, respectively.…”

Clinical evidence and potential mechanisms of traditional Chinese medicine for refractory heart failure: a literature review and perspectives

“…Shengmai injection ( 56 ) can alleviate symptoms such as systemic fatigue, lower limb edema, and liver enlargement, as well as alleviate symptoms of total heart failure, such as jugular vein dilation and purple forceps. Shenfu injection ( 51 ), Shenmai injection ( 57 ), Sofre Injection ( 55 ), Xinmailong injection ( 58 ), and Yiqifumai injection ( 59 ) can increase the 6-min walking distance of patients and improve exercise endurance. Astragalus injection ( 52 ) and Sofre injection ( 55 ) can shorten hospitalization time and reduce the rate of readmission.…”

“…Biochemical indicators Shenfu injection ( 51 , 61 ), Shenqi injection ( 68 ), Astragalus injection ( 65 ), Salviae Miltiorrhizae and Ligustrazine Hydrochloride injection ( 67 ), Xinmailong injection ( 58 , 69 ), and Yiqifumai injection ( 59 ) can reduce the levels of NT-proBNP or BNP. Shenfu injection ( 61 – 63 ) can reduce the levels of inflammatory factors hs-CRP and IL-6, and it can also reduce the levels of CK-MB, cTnT, E-selection (ES), and H-FABP, and alleviate myocardial injury.…”